Status of the implementation of pharmacogenetics in clinical practice in Spain: from regional to national initiatives
Maria Apellaniz-Ruiz, Jordi Barrachina, Paula Castro-Sanchez, Ana Comes-Raga, Xandra García-González, Almudena Gil-Rodriguez, Elixabet Lopez-Lopez, Olalla Maroñas, Rocío Morón, Javier Muriel, Gladys G. Olivera, Pau Riera, Miriam Saiz-Rodríguez, Sara Salvador-Martín, Carla Sans-Pola, Hugo Tejera-Pérez, Alejandro Velasco-Ruiz, Zoraida Verde, Daniel Wang, Ana E. Rodríguez-Vicente, Rocio Nunez-TorresAbstract
Introduction
Pharmacogenetics (PGx) has the potential to improve patient care, allowing to transform medical interventions by providing personalized therapeutic strategies. Scientific evidence supports the use of PGx in clinical practice and international organizations are developing clinical guidelines to facilitate the utilization of PGx testing. However, clinical implementation of PGx is limited and unequal worldwide.
Content
This review summarizes regional and national Spanish initiatives to implement PGx in the clinical practice.
Summary and Outlook
Diverse strategies to implement PGx in healthcare are applied across countries or even in the different regions of a specific country. Such was the case of Spain, a European country with 17 Autonomous Regions and two Autonomous Cities, each one with capacity to manage their own healthcare systems. Nevertheless, during the past years, many initiatives and strategies have been launched in Spain to develop different aspects of PGx. Importantly, the National Healthcare System has approved a PGx testing catalogue. This review highlights the crucial work and efforts of scientific societies (like the Spanish Society of Pharmacogenetics and Pharmacogenomics), of experts in PGx, of healthcare providers and of governmental parties in the implementation of PGx to personalize patient therapy, focused in Spain.